Business Wire

New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes


Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olodaterol in improving symptoms and lung function as well as patients’ satisfaction when inhaling from and handling the tiotropium/olodaterol soft-mist inhaler.1,2,3,4 The results of these studies reinforce the importance of patient needs and preferences as well as patients’ ability to properly inhale when prescribing inhaler therapy for COPD management.

“The importance of matching a specific inhaled therapy with patients’ personal needs and preferences cannot be overstated in COPD management,” said Prof Paola Rogliani, Head of Clinical Respiratory Unit, Policlinico Tor Vergata, Rome, Italy. “A novel bidimensional, pooled analysis enabled us to directly compare six LAMA/LABA fixed-dose combinations and demonstrate that tiotropium/olodaterol improved patient outcomes more than the other treatments in the class. Varying efficacy and safety of combinations in the same class should be considered for a patient-centred approach in COPD.”

Data presented at ERS reinforces the benefits of tiotropium/olodaterol LAMA/LABA* therapy in improving patient outcomes, specifically:1,4

- A pooled analysis exploring the effect of step-up COPD treatment from tiotropium at baseline to tiotropium/olodaterol,4 showed that optimising bronchodilation with tiotropium/olodaterol led to clinically relevant improvements in lung function, health status and breathlessness.4
- A bidimensional comparative analysis looked at the efficacy and safety profile of six LAMA/LABA fixed-dose combinations and found tiotropium/olodaterol surpassed all others in-class in terms of efficacy, while also having fewer cardiovascular serious adverse events.1

Further data presented reinforce satisfaction, inhaleability and ease of use associated with the tiotropium/olodaterol inhaler:2,3

- An open-label, observational study evaluating patients’ general condition as well as treatment and device satisfaction in COPD patients treated with tiotropium/olodaterol, found improved general condition as well as high satisfaction with handling and inhaling from the tiotropium/olodaterol device as reported by patients.2
- To guide the development of an enhanced tiotropium/olodaterol inhaler, two formative studies evaluating COPD patients’ general handling of the tiotropium/olodaterol and the tiotropium/olodaterol re-usable inhalers confirmed that a patient-centric design led to an enhanced tiotropium/olodaterol re-usable inhaler with improved usability and easier-to-read dose indicator.3

These findings are significant because in addition to the importance of individualising treatment, the internationally-recognised GOLD guidance document emphasises considering patient preferences and ability to use their inhaler when prescribing a specific COPD therapy.5 Studies suggest that up to 52% of COPD patients struggle to inhale from their device (including those with mild disease),6,7 and the ability to properly inhale medication plays a key role in COPD management.8,9

“As a company, we have been developing therapies and inhaler devices for people with respiratory conditions for almost a century,” said Dr Alberto de la Hoz, Global Head of Medical Affairs, Respiratory Franchise at Boehringer Ingelheim. “The data presented at ERS underscore the efficacy of tiotropium/olodaterol as a treatment for COPD patients with different clinical characteristics and needs, and how the Respimat® re-usable was enhanced based on HCP and patient feedback, addressing their evolving needs and preferences.”

Boehringer Ingelheim will present data from 11 abstracts relating to the COPD portfolio, host two scientific symposia and post daily podcasts featuring leading respiratory experts throughout the ERS Congress. To find out more, visit the Boehringer Ingelheim ERS webpage:

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit:

* Long-acting muscarinic antagonists/long-acting beta2 agonists
Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy for the Diagnosis, Management, and Prevention of COPD

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Julia Gußmann
Boehringer Ingelheim
Phone: +49 (6132) 77-171244
Fax: +49 (6132) 72-171244

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia19.10.2019 23:29:00 CESTPress release

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who have one copy of the F508del mutation and another responsive residual function (RF) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. People with CF who have one copy of the F508del mutation and another responsive RF mutation in the CFTR gene will have access to a medicine for the cause of their CF for the first time. In addition, ORKAMBI® (lumacaftor/ivacaftor) is now also reimbursed for the treatment of children with CF ages 2 to 5 who have two copies of the F508del mutation in the CFTR gene. Patients over the age of 6 have already been able to access ORKAMBI® in Australia since October 2018. Following previously received positive recommendations from the Pharmaceutical Benefits Advisory Committee (PB

A&D Resources utvider i Norden19.10.2019 12:57:00 CESTPress release

A&D Resources, den autoriserte distributøren for Hogan Assessments i Danmark og Benelux-landene, utvider forretningsdriften til Finland, Norge og Sverige, noe som gjøre det til den fremste Hogan-distributøren i regionen. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: A&D spesialiserer seg i evaluering og utvikling av enkeltpersoner, grupper og organisasjoner, og er ansett som den fremste evalueringsvirksomheten i Danmark. Denne utvidelsen i Norden kan i stor grad tilskrives organisasjonens suksesshistorie i den omliggende regionen og også på grunn av dens arbeid globalt. «Vi er heldige som har et sterkt omdømme innenfor vår bransje, enten det er i Danmark, Benelux eller utover, og det er fordi vi leverer», sier Hans Ove Dahl, administrerende direktør i A&D. «Vi mener at hvis du bygger opp et talentfullt team ved å bruke Hogans evalueringer, som er allment betraktet som de mest prediktive evalueringene

EURid Launches New Eligibility Criteria19.10.2019 04:30:00 CESTPress release

The top-level internet domain .eu is the eighth largest country code extension on the internet and, as of October 2019, we have more than 3.6 million registrations spread out across Europe. Since its launch in 2006, only companies and individuals residing within the EU and EEA member states have been eligible to register the .eu domain name. However, striving to meet the needs of an ever-changing digital environment, the eligibility criteria for the registration of .eu domain name has now been extended to all EU citizens living around the world. With millions of Europeans living around the world – our hope is to provide these individuals, living far from their native lands, with a personal online platform through which they can share their stories with families and friends back home. “We are excited to be able to extend the registration criteria to EU citizens around the world. The .eu domain is now closer to your ambitions, achievements and dreams. It is the bridge connecting you to y

ams to Launch New Takeover Offer for OSRAM at EUR 41.00 Per Share With Minimum Acceptance Threshold of 55%18.10.2019 17:16:00 CESTPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, announces that it intends to launch a new all-cash takeover offer for OSRAM Licht AG ("OSRAM") for 100% of the share capital of OSRAM at a price of EUR 41.00 per share ("Offer"). The Offer which represents a premium of 42% to the undisturbed OSRAM share price of EUR 28.92 as of 2 July 2019 will be launched by ams Offer GmbH, a newly incorporated, wholly owned subsidiary of ams. ams is the largest shareholder in OSRAM with a direct shareholding of 19.99% which ams will not exceed outside of the Offer. As a result of ams' shareholder position, ams has lowered the minimum acceptance threshold to 55%. Winning way forward for ams and OSRAM The combination of ams and OSRAM allows ams to create a global leader in sensor solutio

Resecurity Appoints Selene Giupponi Managing Director of Resecurity Europe18.10.2019 15:38:00 CESTPress release

Resecurity, a cybersecurity company that delivers in-depth analysis layered on top of the most comprehensive, exclusive sets of data from the Deep and Dark Web, announces that Selene Giupponi has joined as Managing Director and will be based in Italy. A digital forensics expert, Selene adds significant value to Resecurity’s operations in Europe. This press release features multimedia. View the full release here: Resecurity Appoints Selene Giupponi Managing Director of Resecurity Europe (Photo: Business Wire) Selene has extensive expertise in digital forensics and is often called as an expert witness regarding digital and mobile forensics on domestic and international cases, investigations and court trials. She is a specialized IT trainer in Italy and teaches digital, mobile, cloud and mainframe forensics, cybercrime and information security at various Italian universities. “Selene brings a depth of experience to our team and we

Secure-24 Completes Acquisition of Symmetry Corporation18.10.2019 14:20:00 CESTPress release

NTT Ltd., the newly formed, world-leading global technology services provider, and Symmetry Holding Inc. (Symmetry), a U.S.-based leading provider of SAP managed services, today announced that Secure-24 Intermediate Holdings, Inc. (Secure-24), part of the Managed Services division of NTT Ltd., has completed the acquisition of Symmetry Corporation effective October 17, 2019. “The powerful business combination of Secure-24 and Symmetry leverages the strengths of both companies around Secure-24’s foundation of delivering managed IT operations, application hosting and cloud services to enterprises worldwide,” said Mike BeDell, Chief Executive Officer, Secure-24. “As we begin to integrate Symmetry’s portfolio into Secure-24’s portfolio, through a shared vision, we look forward to providing even greater value that accelerates our clients’ business success.” Symmetry, headquartered in Brookfield, Wisconsin, will expand the scale of SAP managed services capabilities of Secure-24 and bring new